93
Views
4
CrossRef citations to date
0
Altmetric
Review

Polyol pathway and RAGE: a central metabolic and signaling axis in diabetic complications

, &
Pages 65-75 | Published online: 10 Jan 2014

References

  • Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat. Rev. Drug Discov.8(5), 417–429 (2009).
  • Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response – the evidence mounts. J. Leukoc. Biol.86, 505–512 (2009).
  • Kaneko M, Bucciarelli L, Hwang YC et al. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann. NY Acad. Sci.1043, 702–709 (2005).
  • Williamson JR, Chang K, Frangos M et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes42(6), 801–813 (1993).
  • Turk Z. Glycotoxines, carbonyl stress and relevance to diabetes and its complications. Physiol. Res. (2009) (Epub ahead of print).
  • Niwa T. 3-deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J. Chromatogr.731(1), 23–36 (1999).
  • Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical Type 1 diabetes. Diabetologia48(8), 1590–1603 (2005).
  • Jono T, Nagai R, Lin X et al. N-e-(carboxymethyl)lysine and 3-DG-imidazolone are major AGE structures in protein modification by 3-deoxyglucosone. J. Biochem.136(3), 351–358 (2004).
  • Li W, Hamada Y, Nakashima E et al. Suppression of 3-deoxyglucosone and heparin-binding epidermal growth factor-like growth factor mRNA expression by aldose reductase inhibitor in rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun.314(2), 370–376 (2004).
  • Hamada Y, Nakamura J, Naruse K et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Ne-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care23(10), 1539–1544 (2000).
  • Nakamura N, Yamazaki K, Satoh A et al. Effects of epalrestat on plasma levels of advanced glycation end products in patients with Type 2 diabetes. In Vivo17(2), 177–180 (2003).
  • Kilhovd BK, Giardino I, Torjesen PA et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with Type 2 diabetes. Metabolism52(2), 163–167 (2003).
  • Richard JP. Mechanism for the formation of methylglyoxal from triosephosphates. Biochem. Soc. Trans.21(2), 549–553 (1993).
  • Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification – a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol.27, 565–573 (1996).
  • Dhar A, Desai K, Kazachmov M, Yu P, Wu L. Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metabolism57(9), 1211–1220 (2008).
  • Thornalley PJ. Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact.111–112, 137–151 (1998).
  • Phillips SA, Mirrlees D, Thornalley PJ. Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem. Pharmacol.46(5), 805–811 (1993).
  • Diaz-Flores M, Ibanez-Hernandez MA, Glavan RE et al. Glucose-6-phosphate dehydrogenase activity and NADPH/NADP+ ratio in liver and pancreas are dependent on the severity of hyperglycemia in rat. Life Sci.78(22), 2601–2607 (2006).
  • Yang MS, Chan HW, Yu LC. Glutathione peroxidase and glutathione reductase activities are partially responsible for determining the susceptibility of cells to oxidative stress. Toxicology226(2–3), 126–130 (2006).
  • Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest.91(5), 2155–2168 (1993).
  • Schmidt AM, Hori O, Chen JX et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest.96(3), 1395–1403 (1995).
  • Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem.283(40), 27255–27269 (2008).
  • Kislinger T, Fu, C, Huber B et al. N(e)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem.274(44), 31740–31749 (1999).
  • Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy – are these receptors valid therapeutic targets. Curr. Drug Targets10(1), 42–50 (2009).
  • Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes46(2), 292–300 (1997).
  • Hwang YC, Kaneko M, Bakr S et al. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J.18(11), 1192–1199 (2004).
  • Aleshin A, Ananthakrishnan R, Li Q et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and Stat signaling in a murine model. Am. J. Physiol. Heart Circ. Physiol.294, 1823–1832 (2008).
  • Chang JS, Wendt T, Qu W et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation endproducts. Circ. Res.102, 905–913 (2008).
  • Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature405, 354–360 (2000).
  • Zill H, Gunther R, Erbersdobler HF, Folsch UR, Faist V. RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem. Biophys. Res. Commun.288, 1108–1111 (2001).
  • Dukic-Stefanovic S, Gasic-Milenkovic J, Deuther-Conrad W, Munch G. Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). J. Neurochem.87, 44–55 (2003).
  • Harja E, Bu DX, Hudson BI et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J. Clin. Invest.118, 183–194 (2008).
  • Guo J, Ananthakrishnan R, Qu W et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J. Am. Soc. Nephrol.19, 961–972 (2008).
  • Origlia N, Righi M, Capsoni S et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction. J. Neurosci.28, 3521–3530 (2008).
  • Sakaguchi T, Yan SF, Yan SD et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest.111, 959–972 (2003).
  • Reddy MA, Li SL, Sahar S et al. Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation endproducts in vascular smooth muscle cells. J. Biol. Chem.281, 13685–13693 (2006).
  • Vincent AM, Perrone L, Sullivan KA et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology148, 548–558 (2007).
  • Fukami K, Ueda S, Yamaghishi S et al. AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type 1 receptor interaction. Kidney Int.66, 2137–2147 (2004).
  • Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem.274, 19919–19924 (1999).
  • Sorci G, Riuzzi F, Arcuri C, Giambanco I, Donato R. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol. Cell. Biol.24, 4880–4894 (2004).
  • Hudson BI, Kalea AZ, Del Mar Arriero M et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem.283, 34457–34468 (2008).
  • Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation endproducts (RAGE) directly binds to ERK by a D-domain like docking site. FEBS Lett.550, 107–113 (2003).
  • Tang WH, Wu S, Wong TM, Chung SK, Chung SS. Polyol pathway mediates iron-induced oxidative injury in ischemic-reperfused rat heart. Free Radic. Biol. Med.45(5), 602–610 (2008).
  • Qui L, Wu X, Chau JF et al. Aldose reductase regulates hepatic peroxisome proliferator-activated receptor a phosphorylation and activity to impact lipid homeostasis. J. Biol. Chem.283(25), 17175–17183 (2008).
  • Jiang T, Che Q, Lin Y, Li H, Zhang N. Aldose reductase regulates TGF-β1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells. Nephrology11(2), 105–112 (2006).
  • Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates Jak/STAT signaling: a novel axis in myocardial ischemic injury. FASEB J.19(7), 795–797 (2005).
  • Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem.277(35), 32063–32070 (2002).
  • Trueblood NA, Ramasamy R. Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am. J. Physiol.275, H75–H82 (1998).
  • Ramasamy R, Trueblood NA, Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am. J. Physiol.275, H195–H203 (1998).
  • Hwang YC, Sato S, Tsai J et al. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J.16, 243–245 (2002).
  • Ramasamy R, Liu H, Oates PJ, Schaefer S. Attenuation of ischemia induced increases in sodium and calcium by an aldose reductase inhibitor zopolrestat. Cardiovasc. Res.42, 130–139 (1999).
  • Ananthakrishnan R, Kaneko M, Hwang YC et al. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondria permeability transition pore. Am. J. Physiol. Heart Circ. Physiol.296, H333–H341 (2009).
  • Johnson BF, Nesto RW, Pfeifer MA et al. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care27(2), 448–454 (2004).
  • Bucciarelli LG, Kaneko M, Ananthakrishnan R et al. Receptor for advanced glycation endproducts: key modulator of myocardial ischemic injury. Circulation113(9), 1226–1234 (2006).
  • Bucciarelli LG, Ananthakrishnan R, Hwang YC et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes57(7), 1941–1951 (2008).
  • Sun M, Yokoyama M, Ishiwata T, Asano G. Deposition of advanced glycation endproducts (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int. J. Exp. Pathol.79(4), 207–222 (1998).
  • Kato T, Yamashita T, Sekiguchi A et al. AGEs–RAGE system mediates atrial structural remodeling in the diabetic rat. J. Cardiovasc. Electrophysiol.19(4), 415–420 (2008).
  • Andrassy M, Volz HC, Igwe JC et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation117(25), 3216–3226 (2008).
  • Gao ZQ, Yang C, Wang YY et al. RAGE upregulation and nuclear factor kB activation associated with ageing rat cardiomyocyte dysfunction. Gen. Physiol. Biophys.27(3), 152–158 (2008).
  • Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin induced cardiomyocyte dysfunction via the receptor for advanced glycation endproducts. Circ. Res.102(10), 1239–1246 (2008).
  • Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-α induced expression of adhesion molecules in endothelial cells. FASEB J.18(11), 1209–1218 (2004).
  • Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.28(6), 1137–1143 (2008).
  • Dan Q, Wong R, Chung SK, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion. Life Sci.76(4), 445–459 (2004).
  • Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem.277(35), 32063–32070 (2002).
  • Ruef J, Liu SQ, Bode C et al. Involvement of aldose reductase in vascular smooth muscle growth and lesion formation after arterial injury. Arterioscler. Thromb. Vasc. Biol.20(7), 1745–1752 (2000).
  • Vikramadithyan RK, Hu Y, Noh HL et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest.115(9), 2434–2443 (2005).
  • Noh H-L, Hu Y, Park T-S et al. Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat. J. Pharmacol. Exp. Ther.328(2), 496–503 (2009).
  • Burke AP, Kolodgie FD, Zieske A et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol.24(7), 1266–1271 (2004).
  • Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med.4(9), 1025–1031 (1998).
  • Kislinger T, Tanji N, Wendt T et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol.21(6), 905–910 (2001).
  • Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation106(22), 2827–2835 (2002).
  • Wendt T, Harja E, Bucciarelli L et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of Type 2 diabetes. Atherosclerosis185(1), 70–77 (2006).
  • Soro-Paavonen A, Watson AM, Li J et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes57(9), 2461–2469 (2008).
  • Harja E, Bu DX, Hudson BI et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J. Clin. Invest.118(1), 183–194 (2008).
  • Sun L, Ishida T, Yasuda T et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc. Res.82(2), 371–381 (2009).
  • Mylari BL, Beyer TA, Siegel TW. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxyO2(5H)-oxopyrrole-4-carboxylate, and its congeners. J. Med. Chem.34, 1011–1018 (1991).
  • Sarges R, Oates PJ. Aldose reductase inhibitors: recent developments. Prog. Drug Res.40, 99–161 (1993).
  • Alexiou P, Pegkidou K, Chatzopoulou M, Nocolaou I, Demopoulos VJ. Aldose reductase enzyme and its implication to major health problems of the 21st century. Curr. Med. Chem.16(6), 734–752 (2009).
  • Bank N, Mower P, Aynedjian HS, Wilkes BM, Silverman S. Sorbinil prevents glomerular hyperperfusion in diabetic rats. Am. J. Physiol.256, F1000–F1006 (1989).
  • Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic NADH/NAD+. Kidney Int.41, 778–788 (1992).
  • Beyer-Mears A, Murray FT, Cruz E, Roundtree J, Sciadini M. Comparison of sorbinil and ponalrestat diminution of proteinuria in the BB rat. Pharmacology45, 285–291 (1992).
  • Itagaki I, Shimizu K, Kamanaka Y et al. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Diabetes Res. Clin. Pract.25, 147–154 (1994).
  • Donnelly SM, Zhou XP, Huang JT, Whiteside CI. Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat. Biochem. Cell Biol.74, 355–362 (1996).
  • Keogh RJ, Dunlop ME, Larkins RG. Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C and phospholipase A2 activation. Metabolism46, 41–47 (1997).
  • Daniels BS, Hosetter TH. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes38, 981–986 (1989).
  • Osterby R, Gundersen HJ. Glomerular basement membrane thickening in streptozotocin-diabetic rats despite treatment with an aldose reductase inhibitor. J. Diabetes Complications3, 149–153 (1989).
  • Yamaoka T, Nishimura C, Yamashita K et al. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia38, 255–261 (1995).
  • Dan Q, Wong RL, Yin S, Chung SK, Chung SS, Lam KS. Interaction between the polyol pathway and non-enzymatic glycation on mesangial cell gene expression. Nephron Exp. Nephrol.98(3), e89–e99 (2004).
  • Passariello N, Sepe J, Marrazzo G et al. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDMM subjects with nephropathy. Diabetes Care16, 789–795 (1993).
  • Iso K, Tada H, Koboki K, Inokuchi T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic subjects. J. Diabetes Complications15, 241–244 (2001).
  • Zopolrestat Diabetic Nephropathy Study Group. Effect of zopolrestat on urinary albumin excretion rate in Type 1 diabetic subjects. Presented at: The Annual Meeting of the American Society of Nephrology 4–9 November, PA, USA (2008) (Abstract).
  • Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol.11, 1656–1666 (2000).
  • Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol.162(4), 1123–1127 (2003).
  • Flyvbjerg A, Denner L, Schrijvers BF et al. Long-term renal effects of a neutralizing RAGE antibody in obese Type 2 diabetic mice. Diabetes53, 166–172 (2004).
  • Jensen LJ, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A. Renal effects of a neutralizing RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol.188, 493–501 (2006).
  • Myint KM, Yamamoto Y, Doi T et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes55, 2510–2522 (2006).
  • Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, resilient. Exp. Diabetes Res.2007, 61038 (2007).
  • Schemmel KE, Padiyara RS, D’Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J. Diabetes Complications DOI: 10.1016/j.jdiacomp.2009.07.005 (2009) (Epub ahead of print).
  • Barile GR, Schmidt AM. RAGE and its ligands in retinal disease. Curr. Mol. Med.7, 758–765 (2007).
  • Toth C, Martinez J, Zochodne DW. RAGE, diabetes and the nervous system. Curr. Mol. Med.7, 766–776 (2007).
  • Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev.26, 380–392 (2005).
  • Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Exp. Opin. Invest. Drugs8, 2095–2119 (1999).
  • Neatmat-Allah M, Feeney SA, Savage DA et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus. Diabetic Med.18, 906–914 (2001).
  • Hudson BI, Stickland MH, Futers TS, Grant PJ. Effect of novel polymorphisms of the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes50(6), 1505–1511.
  • Kankova K, Stejskalova A, Hertlova M, Znojil V. Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in Type 2 diabetes mellitus. Nephrol. Dial. Transplant.20(6), 1093–1102 (2005).
  • PKC-DRS2 Group, Aiello LP, Davis MD et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
  • Cherney DZ, Konvalinka A, Zinman B et al. Effect of protein kinase C b inhibition on renal hemodynamic function and urinary biomarkers in humans with Type 1 diabetes: a pilot study. Diabetes Care32(1), 91–93 (2009).
  • Rashba EJ, Reich EP, Janeway CA, Sherwin RS. Type 1 diabetes mellitus: an imbalance between effector and regulatory T cells? Acta Diabetol.30(2), 61–69 (1993).
  • Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol.25(1), 4–7 (2004).
  • Kaufmann JJ, Langdon EA, Stein JJ, Burt FB. Cancer of the bladder. Combined 5-fluorouracil and cobalt-60 teletherapy. Calif. Med.101, 334–340 (1964).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.